---
title: "Lymphoma"
order: 4
category: "Hematology"
---

# Lymphoma

## Overview

Lymphomas are a heterogeneous group of hematologic malignancies originating from lymphocytes (B cells, T cells, or NK cells) in lymph nodes or extranodal lymphoid tissues. They are broadly classified into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), which differ in histology, clinical behavior, and treatment approaches. Understanding lymphoma classification, staging, and treatment strategies is essential for optimal patient management.

### Classification

**Two major categories**:
1. **Hodgkin lymphoma** (HL): Characterized by Reed-Sternberg cells
   - Classical Hodgkin lymphoma (95%)
   - Nodular lymphocyte-predominant Hodgkin lymphoma (5%)

2. **Non-Hodgkin lymphoma** (NHL): All other lymphomas
   - B-cell lymphomas (85%)
   - T-cell/NK-cell lymphomas (15%)

### Epidemiology

**Hodgkin lymphoma**:
- Incidence: 2.6 per 100,000 persons per year
- ~8,000 new cases annually in US
- Bimodal age distribution: Peak in 20s, second peak after age 55
- Slightly more common in males (M:F = 1.4:1)
- 5-year survival: 88%

**Non-Hodgkin lymphoma**:
- Incidence: 19 per 100,000 persons per year
- ~80,000 new cases annually in US
- Median age: 66 years
- More common in males
- 5-year survival: 73% (varies widely by subtype)
- Incidence increasing over past decades

**Most common NHL subtypes**:
- Diffuse large B-cell lymphoma (DLBCL): 30-40%
- Follicular lymphoma: 20-25%
- Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): 7%
- Mantle cell lymphoma: 6%
- Marginal zone lymphoma: 7-8%
- Peripheral T-cell lymphoma: 10%

## Pathophysiology

### Hodgkin Lymphoma

**Characteristic cell**: Reed-Sternberg (RS) cell
- Large, binucleated or multinucleated cell with prominent eosinophilic nucleoli ("owl's eye" appearance)
- CD15+, CD30+
- Derived from germinal center or post-germinal center B cells
- RS cells are rare (<1% of tumor mass); majority is reactive inflammatory infiltrate

**Classical Hodgkin lymphoma subtypes**:
1. **Nodular sclerosis** (60-70%):
   - Most common subtype
   - Lacunar cells (RS cell variant)
   - Fibrous bands dividing lymph node into nodules
   - Mediastinal involvement common
   - Young adults, females

2. **Mixed cellularity** (20-25%):
   - Numerous classic RS cells
   - Mixed inflammatory infiltrate
   - Associated with HIV, EBV
   - Older patients

3. **Lymphocyte-rich** (5%):
   - Abundant lymphocytes, few RS cells
   - Best prognosis

4. **Lymphocyte-depleted** (<5%):
   - Numerous RS cells, few lymphocytes
   - Poorest prognosis
   - Associated with HIV

**Nodular lymphocyte-predominant Hodgkin lymphoma** (NLPHL):
- "Popcorn cells" (L&H cells, lymphocytic and histiocytic cells)
- CD20+, CD15-, CD30-
- Excellent prognosis
- May transform to DLBCL

**Risk factors**:
- EBV infection (30-40% of cases, especially mixed cellularity)
- Immunodeficiency (HIV, post-transplant)
- Family history (siblings have 3-7 fold increased risk)
- Autoimmune disorders

### Non-Hodgkin Lymphoma

**Diffuse large B-cell lymphoma (DLBCL)**:
- Aggressive B-cell lymphoma
- Diffuse proliferation of large B cells
- CD19+, CD20+, CD79a+, surface Ig+
- **Cell of origin subtypes** (gene expression profiling):
  - Germinal center B-cell-like (GCB): Better prognosis
  - Activated B-cell-like (ABC): Poorer prognosis
- **Molecular alterations**: BCL2, BCL6, MYC rearrangements; TP53, MYD88 mutations
- **Double-hit/triple-hit lymphoma**: MYC + BCL2 and/or BCL6 rearrangements (aggressive, poor prognosis)

**Follicular lymphoma**:
- Indolent B-cell lymphoma
- Neoplastic follicles (follicular growth pattern)
- CD19+, CD20+, CD10+, BCL2+, BCL6+
- **t(14;18) translocation**: BCL2-IGH fusion (85%), BCL2 overexpression (inhibits apoptosis)
- **Grading**:
  - Grade 1-2: Indolent (0-15 centroblasts per high-power field)
  - Grade 3: Aggressive (>15 centroblasts per high-power field)
- Transforms to DLBCL in 2-3% per year

**Mantle cell lymphoma** (MCL):
- Aggressive B-cell lymphoma (with some indolent cases)
- CD19+, CD20+, CD5+, cyclin D1+
- **t(11;14) translocation**: CCND1-IGH fusion (>95%), cyclin D1 overexpression (drives cell cycle)
- Extranodal involvement common (GI tract, bone marrow)
- Poor prognosis historically (median survival 3-5 years), improved with newer therapies

**Burkitt lymphoma**:
- Highly aggressive B-cell lymphoma
- CD19+, CD20+, CD10+, BCL6+, Ki-67 ~100% (very high proliferation)
- **MYC translocation**: t(8;14) (80%), t(2;8), t(8;22)
- **Three clinical variants**:
  - Endemic (African): EBV-associated, jaw/facial bones in children
  - Sporadic: Abdomen (ileocecal region), children/young adults in Western countries
  - Immunodeficiency-associated: HIV patients
- "Starry sky" appearance (macrophages among tumor cells)
- Rapidly growing, high tumor lysis risk

**Marginal zone lymphomas**:
- Indolent B-cell lymphomas
- Three types:
  - **Extranodal marginal zone (MALT lymphoma)**: Mucosa-associated lymphoid tissue
    - Stomach (H. pylori-associated), salivary glands, thyroid, lung
    - t(11;18) BIRC3-MALT1 (most common translocation)
  - **Splenic marginal zone lymphoma**: Spleen, bone marrow, blood
  - **Nodal marginal zone lymphoma**: Lymph nodes

**Peripheral T-cell lymphomas** (PTCL):
- Heterogeneous group of aggressive T-cell lymphomas
- **PTCL, not otherwise specified (NOS)**: Most common, lack defining features
- **Anaplastic large cell lymphoma (ALCL)**:
  - CD30+, ALK+ or ALK-
  - t(2;5) NPM-ALK (ALK+, better prognosis)
- **Angioimmunoblastic T-cell lymphoma (AITL)**:
  - Systemic symptoms (fever, rash, hypergammaglobulinemia)
- **Enteropathy-associated T-cell lymphoma (EATL)**: Celiac disease-associated
- Generally poor prognosis (except ALK+ ALCL)

**Risk factors for NHL**:
- Immunodeficiency: HIV, post-transplant, congenital immunodeficiency
- Autoimmune disorders: Sjögren syndrome, rheumatoid arthritis, SLE, celiac disease
- Infections: EBV (Burkitt, PTCL), HTLV-1 (adult T-cell leukemia/lymphoma), HCV (marginal zone), H. pylori (gastric MALT)
- Chronic inflammation
- Prior chemotherapy/radiation

## Clinical Presentation

### Hodgkin Lymphoma

**Lymphadenopathy** (painless):
- **Cervical/supraclavicular nodes**: Most common presentation (60-80%)
- Mediastinal nodes (60%, especially nodular sclerosis)
- Axillary, inguinal nodes less common
- **Contiguous spread**: Spreads to adjacent lymph node groups (predictable pattern)
- Nodes: Firm, rubbery, non-tender, mobile initially

**B symptoms** (30-40%):
- Fever >38°C (Pel-Ebstein fever: cyclic fevers)
- Drenching night sweats
- Unintentional weight loss >10% body weight in 6 months
- Presence of B symptoms upstages disease

**Pruritus** (10-15%):
- Generalized itching without rash
- May precede diagnosis by months

**Alcohol-induced pain** (rare but characteristic):
- Pain in involved lymph nodes after alcohol consumption

**Constitutional symptoms**:
- Fatigue, malaise

**Mediastinal involvement**:
- Cough, dyspnea, chest pain
- Superior vena cava syndrome (if large mediastinal mass)

**Extranodal involvement** (rare):
- Bone marrow, liver, spleen, lung

### Non-Hodgkin Lymphoma

**Lymphadenopathy** (painless):
- **Peripheral lymph nodes**: Cervical, axillary, inguinal
- May wax and wane (especially indolent lymphomas)
- **Non-contiguous spread**: Any lymph node group may be involved

**B symptoms** (20-30%):
- More common in aggressive lymphomas

**Extranodal involvement** (40% at diagnosis):
- GI tract: Abdominal pain, bleeding, obstruction, perforation (Burkitt, MALT, mantle cell)
- Bone marrow: Cytopenias
- CNS: Headache, cranial nerve palsies, altered mental status (high-grade lymphomas, HIV-associated)
- Liver, spleen
- Skin: Papules, nodules, plaques (cutaneous T-cell lymphoma, DLBCL)
- Waldeyer ring (tonsils, nasopharynx)

**Subtype-specific presentations**:
- **DLBCL**: Rapidly enlarging lymphadenopathy, may present as localized extranodal mass
- **Follicular lymphoma**: Indolent, waxing/waning lymphadenopathy, often disseminated at diagnosis
- **Mantle cell lymphoma**: Lymphadenopathy, splenomegaly, GI involvement (lymphomatous polyposis)
- **Burkitt lymphoma**: Rapidly growing abdominal mass, jaw mass (endemic), tumor lysis syndrome
- **MALT lymphoma**: Symptoms related to site (dyspepsia for gastric MALT)

**Superior vena cava syndrome**:
- Mediastinal mass compressing SVC
- Facial swelling, neck vein distension, dyspnea, stridor
- Oncologic emergency

**Tumor lysis syndrome**:
- Rapid cell turnover (Burkitt, other high-grade lymphomas)
- Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, AKI

### Physical Examination

**Lymph nodes**:
- Painless, firm, rubbery (HL) or soft (NHL)
- May be matted (coalescent nodes)
- Size, location, mobility

**Waldeyer ring**: Examine tonsils, oropharynx

**Abdomen**:
- Hepatomegaly, splenomegaly
- Abdominal masses

**Skin**: Examine for lesions (cutaneous lymphoma, leukemia cutis)

**Neurologic examination**: Cranial nerves, motor/sensory exam (CNS involvement)

## Diagnosis

### Initial Evaluation

**Complete blood count (CBC)**:
- Anemia, thrombocytopenia (bone marrow involvement)
- Lymphocytosis (SLL, some NHL)
- Eosinophilia (HL)

**Comprehensive metabolic panel**:
- Renal function (tumor lysis risk)
- Liver function (hepatic involvement)
- Calcium (hypercalcemia in aggressive lymphomas)

**LDH**: Elevated (tumor burden, prognostic marker)

**Uric acid**: Tumor lysis risk

**Hepatitis B and C serology**: Reactivation risk with rituximab, chemotherapy

**HIV testing**: Increased lymphoma risk, impacts prognosis

**Pregnancy test**: Women of childbearing age

### Tissue Diagnosis

**Excisional lymph node biopsy**: Gold standard
- Entire lymph node removed (preserves architecture)
- Core needle biopsy: Acceptable if excisional biopsy not feasible
- **Avoid fine needle aspiration**: Insufficient for diagnosis

**Histopathology**:
- H&E staining: Morphology
- Immunohistochemistry: Cell surface markers (CD antigens)
- Flow cytometry: Immunophenotyping

**Molecular studies**:
- FISH: Chromosomal translocations (t(14;18), t(11;14), t(8;14), MYC, BCL2, BCL6 rearrangements)
- PCR: Clonality (Ig gene or TCR gene rearrangement), specific translocations

### Hodgkin Lymphoma Diagnosis

**Histopathology**:
- Reed-Sternberg cells: CD15+, CD30+, CD20- (classical HL)
- Popcorn cells: CD20+, CD15-, CD30- (NLPHL)
- Inflammatory background: Lymphocytes, eosinophils, histiocytes, plasma cells

**Subtypes**: Nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depleted

### Non-Hodgkin Lymphoma Diagnosis

**Immunophenotyping**:
- B-cell markers: CD19, CD20, CD22, CD79a, surface immunoglobulin
- T-cell markers: CD2, CD3, CD5, CD7
- Other: CD10 (follicular center origin), BCL2, BCL6, cyclin D1, Ki-67 (proliferation index)

**DLBCL**:
- Large B cells, diffuse growth pattern
- CD20+, variable CD10, BCL6
- Hans algorithm or gene expression profiling: GCB vs. ABC
- FISH: MYC, BCL2, BCL6 rearrangements (double-hit/triple-hit)

**Follicular lymphoma**:
- Neoplastic follicles
- CD20+, CD10+, BCL2+
- t(14;18) (85%)
- Grade 1-3 based on centroblast count

**Mantle cell lymphoma**:
- CD20+, CD5+, cyclin D1+
- t(11;14) (>95%)

**Burkitt lymphoma**:
- Medium-sized B cells, basophilic cytoplasm
- CD20+, CD10+, BCL6+, Ki-67 ~100%
- MYC translocation (t(8;14), t(2;8), t(8;22))

### Staging

**Ann Arbor staging system** (HL and NHL):
- **Stage I**: Single lymph node region or single extranodal site (IE)
- **Stage II**: ≥2 lymph node regions on same side of diaphragm or localized extranodal involvement (IIE)
- **Stage III**: Lymph node regions on both sides of diaphragm
- **Stage IV**: Disseminated (multifocal) extranodal involvement (liver, bone marrow, lung)

**Modifiers**:
- **A**: Absence of B symptoms
- **B**: Presence of B symptoms (fever >38°C, night sweats, weight loss >10%)
- **E**: Extranodal extension from adjacent lymph nodes
- **S**: Splenic involvement
- **X**: Bulky disease (>10 cm or >1/3 thoracic diameter on chest X-ray)

**Lugano modification** (2014):
- Incorporates PET-CT findings
- Limited stage: I-II without adverse features
- Advanced stage: III-IV

**Staging workup**:
- **PET-CT scan**: Functional imaging (FDG-avid lymphomas: HL, DLBCL, follicular grade 3, mantle cell)
  - Initial staging
  - Response assessment (Deauville 5-point scale)
- **CT scan**: Chest, abdomen, pelvis with contrast (if PET not available or non-FDG-avid lymphomas)
- **Bone marrow biopsy**: Hodgkin lymphoma (if stage I-II), indolent NHL, mantle cell lymphoma
  - Not needed if PET+ bone marrow or stage IV by other criteria
- **Lumbar puncture**: High-risk NHL (Burkitt, lymphoblastic, HIV-associated, testicular, paranasal sinus, epidural)

**International Prognostic Score (IPS)** for Hodgkin lymphoma:
- Age ≥45 years
- Male sex
- Stage IV
- Hemoglobin <10.5 g/dL
- WBC ≥15,000/μL
- Lymphocytes <600/μL or <8% of WBC
- Albumin <4 g/dL
- Each factor = 1 point; higher score = worse prognosis

**International Prognostic Index (IPI)** for aggressive NHL (DLBCL):
- Age >60 years
- Stage III-IV
- Elevated LDH
- ECOG performance status ≥2
- >1 extranodal site
- Each factor = 1 point
- Risk groups: Low (0-1), low-intermediate (2), high-intermediate (3), high (4-5)

**Follicular Lymphoma International Prognostic Index (FLIPI)**:
- Age >60 years
- Stage III-IV
- Hemoglobin <12 g/dL
- LDH elevated
- >4 nodal areas involved
- Risk groups: Low (0-1), intermediate (2), high (≥3)

## Treatment

### Hodgkin Lymphoma

**Early-stage favorable (IA-IIA without adverse features)**:
- **ABVD chemotherapy**: 2-4 cycles
  - Adriamycin (doxorubicin), bleomycin, vinblastine, dacarbazine
- **Involved-site radiation therapy (ISRT)**: 20-30 Gy (after chemotherapy)
- **Cure rate**: >90%

**Early-stage unfavorable (IA-IIA with adverse features, IB-IIB)**:
- Adverse features: Bulky disease, B symptoms, elevated ESR, ≥3 nodal areas, extranodal disease
- **ABVD**: 4-6 cycles
- **ISRT**: 30 Gy
- **Cure rate**: 80-90%

**Advanced-stage (III-IV)**:
- **ABVD**: 6 cycles (standard)
  - Interim PET after 2 cycles (Deauville score):
    - Score 1-3: Continue ABVD
    - Score 4-5: Consider escalation to BEACOPP
- **BEACOPP (escalated)**: Alternative (more toxic, better efficacy in some trials)
  - Bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone
- **Cure rate**: 70-80%

**Relapsed/refractory Hodgkin lymphoma**:
- **Salvage chemotherapy**:
  - ICE (ifosfamide, carboplatin, etoposide)
  - DHAP (dexamethasone, high-dose cytarabine, cisplatin)
  - GDP (gemcitabine, dexamethasone, cisplatin)
- **Autologous stem cell transplantation (ASCT)**: If chemosensitive disease
  - Cure rate: 40-50%
- **Brentuximab vedotin**: Anti-CD30 antibody-drug conjugate
  - Post-ASCT consolidation (reduces relapse risk)
  - Relapsed/refractory disease
- **PD-1 inhibitors**: Nivolumab, pembrolizumab
  - Relapsed/refractory disease (especially post-ASCT)
  - High response rates
- **Allogeneic stem cell transplantation**: Selected patients with multiple relapses

**Nodular lymphocyte-predominant HL**:
- Excellent prognosis
- Early-stage: ISRT alone or rituximab ± ISRT
- Advanced-stage: R-CHOP or ABVD

### Non-Hodgkin Lymphoma

**Diffuse large B-cell lymphoma (DLBCL)**:

*Localized (stage I-II)*:
- **R-CHOP × 3-4 cycles + ISRT**
  - Rituximab, cyclophosphamide, doxorubicin (Hydroxydaunorubicin), vincristine (Oncovin), prednisone
- **R-CHOP × 6 cycles** (without radiation)
- **Cure rate**: 80-90%

*Advanced stage (III-IV)*:
- **R-CHOP × 6-8 cycles** (every 21 days)
- **Cure rate**: 60-70%

*CNS prophylaxis*:
- High-risk features: Testicular, paranasal sinus, epidural, bone marrow, kidney, HIV-associated
- Intrathecal chemotherapy (methotrexate, cytarabine) or high-dose systemic methotrexate

*Relapsed/refractory DLBCL*:
- Salvage chemotherapy (ICE, DHAP, GDP)
- **Autologous stem cell transplantation**: If chemosensitive
  - Cure rate: 30-40%
- **CAR T-cell therapy**: Axicabtagene ciloleucel, tisagenlecleucel (CD19-directed)
  - Relapsed/refractory after ≥2 prior lines
  - Response rate: 50-80%, durable remissions in 30-40%
- **Polatuzumab vedotin**: Anti-CD79b antibody-drug conjugate (with bendamustine-rituximab)
- **Tafasitamab + lenalidomide**: Anti-CD19 antibody + immunomodulator
- **Selinexor**: XPO1 inhibitor

**Follicular lymphoma**:

*Watch and wait* (asymptomatic, low tumor burden):
- No treatment until symptomatic or progressive
- Median time to treatment: 2-3 years

*Indications for treatment*:
- B symptoms
- Cytopenias (bone marrow involvement)
- Bulky disease (>7 cm)
- Rapid progression
- Organ compromise

*Treatment*:
- **R-bendamustine or R-CHOP**: 6 cycles
- **Rituximab maintenance**: Every 8 weeks for 2 years (improves progression-free survival)
- **Localized (stage I-II)**: ISRT (curative in 40-50%)
- **Relapsed/refractory**:
  - Repeat rituximab-based regimen
  - Obinutuzumab (anti-CD20, glycoengineered)
  - Lenalidomide + rituximab
  - PI3K inhibitors: Idelalisib, copanlisib, duvelisib
  - EZH2 inhibitor: Tazemetostat (for EZH2 mutation)
  - CAR T-cell therapy: Axicabtagene ciloleucel
  - Autologous or allogeneic stem cell transplantation
- **Median survival**: 15-20 years (indolent, relapsing/remitting course)

**Mantle cell lymphoma**:

*Asymptomatic, elderly*:
- Watch and wait

*Intensive therapy (young, fit patients)*:
- **R-hyperCVAD alternating with high-dose methotrexate-cytarabine** (8 cycles)
  - Rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone
- **Nordic regimen**: R-maxi-CHOP alternating with high-dose cytarabine
- **Autologous stem cell transplantation**: Consolidation in first remission
- **Median progression-free survival**: 5-10 years

*Less intensive therapy (elderly, unfit patients)*:
- **R-bendamustine**: 6 cycles
- **R-CHOP**: 6-8 cycles
- **Rituximab maintenance**: Improves PFS

*Relapsed/refractory*:
- **BTK inhibitors**: Ibrutinib, acalabrutinib (high response rates, continuous therapy)
- **Lenalidomide + rituximab**
- **Bortezomib-based regimen**: VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone)
- **Brexucabtagene autoleucel**: CAR T-cell therapy
- Allogeneic stem cell transplantation

**Burkitt lymphoma**:
- **Intensive multi-agent chemotherapy**:
  - R-CODOX-M/IVAC (rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate / ifosfamide, etoposide, cytarabine)
  - R-hyperCVAD
- **CNS prophylaxis**: Intrathecal chemotherapy (all patients)
- **Tumor lysis prophylaxis**: Hydration, allopurinol or rasburicase
- **Cure rate**: 70-90% (excellent prognosis with intensive therapy)

**MALT lymphoma**:
- **Gastric MALT (H. pylori-positive)**:
  - **H. pylori eradication**: Triple or quadruple therapy (PPI, antibiotics)
  - Response rate: 60-80% (limited-stage, t(11;18) negative)
  - Monitor response with endoscopy, biopsies at 3, 6, 12 months
- **H. pylori-negative or refractory**:
  - Rituximab monotherapy
  - Radiation therapy (localized)
  - R-chlorambucil or R-bendamustine
- **Non-gastric MALT**: Rituximab, radiation, chemotherapy depending on site and stage
- **Indolent, excellent prognosis**

**Peripheral T-cell lymphomas**:
- **CHOP or CHOEP** (CHOP + etoposide): 6-8 cycles
  - Less effective than in B-cell lymphomas
- **Brentuximab vedotin + CHP**: First-line for CD30+ PTCL (replaces vincristine)
- **Autologous stem cell transplantation**: Consolidation in first remission (selected patients)
- **Relapsed/refractory**:
  - Brentuximab vedotin (CD30+)
  - Romidepsin, belinostat (histone deacetylase inhibitors)
  - Pralatrexate (antifolate)
  - Allogeneic stem cell transplantation
- **Median survival**: 1-3 years (poor prognosis overall, except ALK+ ALCL)

**ALK+ anaplastic large cell lymphoma**:
- **CHOP**: 6 cycles
- **Excellent prognosis**: 5-year survival 70-90%

### Supportive Care

**Tumor lysis syndrome prophylaxis**:
- Hydration: IV fluids 2-3 L/day
- Allopurinol or rasburicase (high-risk)
- Monitor electrolytes, uric acid, LDH, creatinine

**Infection prophylaxis**:
- Pneumocystis jirovecii pneumonia (PCP): Trimethoprim-sulfamethoxazole
- Herpes simplex virus (HSV): Acyclovir
- Hepatitis B reactivation: Antiviral prophylaxis (if HBsAg+ or anti-HBc+)

**Growth factors**:
- G-CSF: If high risk of febrile neutropenia

**Transfusion support**:
- PRBCs, platelets as needed

## Complications

### Treatment-Related Complications

**Chemotherapy toxicity**:
- **Bleomycin**: Pulmonary fibrosis (monitor pulmonary function, avoid O₂ unless necessary)
- **Anthracyclines**: Cardiotoxicity (monitor LVEF, cumulative dose <450 mg/m²)
- **Vincristine**: Peripheral neuropathy
- **Rituximab**: Infusion reactions, immunosuppression, hepatitis B reactivation, PML (rare)

**Radiation toxicity**:
- Hypothyroidism (neck radiation)
- Coronary artery disease (mediastinal radiation)
- Lung fibrosis (mediastinal radiation)
- Secondary malignancies (breast cancer in young women)

**Immunotherapy toxicity**:
- **CAR T-cell therapy**:
  - Cytokine release syndrome (CRS): Fever, hypotension, hypoxemia (treat with tocilizumab, steroids)
  - Immune effector cell-associated neurotoxicity syndrome (ICANS): Encephalopathy, seizures
- **PD-1 inhibitors**: Immune-related adverse events (pneumonitis, colitis, hepatitis, endocrinopathies)

**Stem cell transplantation complications**:
- Graft-versus-host disease (allogeneic)
- Infections (bacterial, fungal, viral)
- Veno-occlusive disease
- Secondary malignancies

### Disease-Related Complications

- **Superior vena cava syndrome**: Mediastinal mass
- **Spinal cord compression**: Epidural involvement (oncologic emergency)
- **CNS involvement**: Lymphomatous meningitis, brain lesions
- **Tumor lysis syndrome**: Burkitt, other high-grade lymphomas
- **Hypercalcemia**: Aggressive lymphomas
- **Cytopenias**: Bone marrow involvement
- **Infections**: Immunosuppression from lymphoma or treatment

### Late Effects

- **Secondary malignancies**: AML/MDS, solid tumors (lung, breast, thyroid)
- **Cardiovascular disease**: From anthracyclines, mediastinal radiation
- **Pulmonary fibrosis**: Bleomycin, radiation
- **Infertility**: Alkylating agents (counsel about fertility preservation)
- **Hypothyroidism**: Neck radiation
- **Chronic fatigue**

## Prognosis

### Hodgkin Lymphoma

**Overall 5-year survival**: 88%
- Early-stage favorable: >95%
- Early-stage unfavorable: 85-95%
- Advanced-stage: 75-85%

**IPS score** (advanced-stage):
- Score 0-1: 80-90% 5-year survival
- Score 2-3: 70-80%
- Score ≥4: 50-60%

**Relapsed/refractory**:
- 40-50% cured with salvage chemotherapy + ASCT
- PD-1 inhibitors, brentuximab improve outcomes

### Non-Hodgkin Lymphoma

**Overall 5-year survival**: 73% (varies widely by subtype)

**DLBCL**:
- Localized: 80-90%
- Advanced-stage: 60-70%
- IPI risk groups:
  - Low (0-1): 85-90%
  - Low-intermediate (2): 70-80%
  - High-intermediate (3): 50-60%
  - High (4-5): 30-40%
- Relapsed/refractory: 30-40% cured with salvage + ASCT

**Follicular lymphoma**:
- Median survival: 15-20 years (indolent, relapsing/remitting)
- 10-year survival: 80%
- Transformation to DLBCL: 2-3% per year, poor prognosis

**Mantle cell lymphoma**:
- Median survival: 5-10 years (improved with intensive therapy, BTK inhibitors)
- Historically poor prognosis (median 3-5 years)

**Burkitt lymphoma**:
- Cure rate: 70-90% with intensive chemotherapy

**MALT lymphoma**:
- Excellent prognosis, indolent
- 10-year survival: 80-90%

**Peripheral T-cell lymphomas**:
- Median survival: 1-3 years (poor prognosis overall)
- ALK+ ALCL: 5-year survival 70-90% (excellent prognosis)

## Key Points

- Lymphomas are classified into Hodgkin lymphoma (Reed-Sternberg cells, contiguous spread, 10% of cases) and non-Hodgkin lymphoma (heterogeneous, non-contiguous spread, 90% of cases)
- Hodgkin lymphoma presents with painless cervical/supraclavicular lymphadenopathy, often with mediastinal involvement; B symptoms and pruritus are common
- Treatment for Hodgkin lymphoma is ABVD chemotherapy ± radiation; cure rate >90% for early-stage, 70-80% for advanced-stage
- DLBCL is the most common aggressive NHL; treated with R-CHOP chemotherapy (cure rate 60-80%); salvage options include ASCT and CAR T-cell therapy
- Follicular lymphoma is the most common indolent NHL; characterized by t(14;18) BCL2 translocation; asymptomatic patients observed, symptomatic patients treated with rituximab-based regimens + maintenance
- Mantle cell lymphoma has t(11;14) cyclin D1 overexpression; treated with intensive chemotherapy (R-hyperCVAD) or R-bendamustine; BTK inhibitors highly effective for relapsed disease
- Burkitt lymphoma is highly aggressive with MYC translocation; requires intensive chemotherapy with CNS prophylaxis and tumor lysis prophylaxis; cure rate 70-90%
- Ann Arbor staging (I-IV) used for both Hodgkin and non-Hodgkin lymphoma; PET-CT is standard for staging FDG-avid lymphomas

## References

1. Ansell SM. Hodgkin Lymphoma: 2018 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2018;93(5):704-715.

2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2018. National Cancer Institute; 2021.

3. Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842-858.

4. Kahl BS, Yang DT. Follicular Lymphoma: Evolving Therapeutic Strategies. Blood. 2016;127(17):2055-2063.

5. Jain P, Wang M. Mantle Cell Lymphoma: 2019 Update on the Diagnosis, Pathogenesis, Prognostication, and Management. Am J Hematol. 2019;94(6):710-725.

6. Molyneux EM, Rochford R, Griffin B, et al. Burkitt's Lymphoma. Lancet. 2012;379(9822):1234-1244.

7. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 2014;32(27):3059-3068.

8. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood. 2016;127(20):2375-2390.

9. Locke FL, Ghobadi A, Jacobson CA, et al. Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial. Lancet Oncol. 2019;20(1):31-42.

10. Younes A, Gopal AK, Smith SE, et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin's Lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
